The Influence of Oxytocin and Prolactin During a First Episode of Psychosis: The Implication of Sex Differences, Clinical Features, and Cognitive Performance
Resumen: Background Approximately 3% of the population suffers a first episode of psychosis (FEP), and a high percentage of these patients subsequently relapse. Because the clinical course following a FEP is hard to predict, it is of interest to identify cognitive and biological markers that will help improve the diagnosis, treatment, and outcome of such events and to define new therapeutic targets. Here we analyzed the plasma oxytocin and prolactin levels during an FEP, assessing their correlation with clinical and cognitive features. Methods The oxytocin and prolactin in plasma was measured in 120 FEP patients and 106 healthy controls, all of whom were subjected to a clinical and neuropsychological assessment. Most patients were under antipsychotics. Statistical analyses aimed to identify factors associated with the FEP and to search for associations between the variables. This study is preliminary and exploratory because the P-values were not corrected for multiple comparisons. Results FEP patients had less oxytocin, more prolactin, and a poor premorbid IQ, and they performed worse in sustained attention. Male patients with higher prolactin levels experienced more severe psychotic symptoms and required higher doses of antipsychotics. Low oxytocin was associated with poor sustained attention in women, whereas low oxytocin and high prolactin in men correlated with better performance in sustained attention. Conclusion Low oxytocin, high prolactin, and poor premorbid IQ and sustained attention are factors associated with an FEP, representing potential therapeutic targets in these patients. These biological factors and cognitive domains might play an important role during a FEP, which could help us to develop new strategies that improve the outcomes of this disorder and that should perhaps be gender specific.
Idioma: Inglés
DOI: 10.1093/ijnp/pyac023
Año: 2022
Publicado en: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 25, 8 (2022), 666–677
ISSN: 1461-1457

Factor impacto JCR: 4.8 (2022)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 65 / 278 = 0.234 (2022) - Q1 - T1
Categ. JCR: CLINICAL NEUROLOGY rank: 49 / 212 = 0.231 (2022) - Q1 - T1
Categ. JCR: PSYCHIATRY rank: 50 / 154 = 0.325 (2022) - Q2 - T1
Categ. JCR: NEUROSCIENCES rank: 80 / 272 = 0.294 (2022) - Q2 - T1

Factor impacto CITESCORE: 7.8 - Pharmacology, Toxicology and Pharmaceutics (Q1) - Medicine (Q1)

Factor impacto SCIMAGO: 1.406 - Pharmacology (Q1) - Psychiatry and Mental Health (Q1) - Pharmacology (medical) (Q1)

Financiación: info:eu-repo/grantAgreement/ES/ISCIII-FIS-FEDER/PI19-00766
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Area Psiquiatría (Dpto. Medicina, Psiqu. y Derm.)

Creative Commons Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial.


Exportado de SIDERAL (2024-03-18-14:43:16)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Artículos



 Registro creado el 2022-07-15, última modificación el 2024-03-19


Versión publicada:
 PDF
Valore este documento:

Rate this document:
1
2
3
 
(Sin ninguna reseña)